AnaptysBio, Inc. (ANAB) Stock Forecast
ANAB analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.62 / 5 from 8 analysts
- Price target
- $87.25 average of analyst targets
- Upside to target
- +87.2% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $0.41
- 52-week range
- $22.06 – $69.81
ANAB analyst ratings
8 analystsNumber of analysts at each rating.
ANAB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ANAB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.80 | $0.30 | $1.29 | $0.52 | +53.1% | 2 |
| Current fiscal year (2026) | $4.35 | $2.49 | $7.06 | −$0.46 | +1,045.7% | 3 |
| Next fiscal year (2027) | $5.07 | $2.69 | $8.77 | $4.35 | +16.5% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ANAB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $33.5M | $28.9M | $40.2M | −56.2% | 3 |
| Current fiscal year (2026) | $101.1M | $53.0M | $136.9M | −56.9% | 3 |
| Next fiscal year (2027) | $171.3M | $47.0M | $259.0M | +69.4% | 6 |
ANAB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ANAB revenue: reported and forecast
ANAB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.38 | $0.38 | $0.38 | $0.80 | $0.80 | +107.2% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.23 | −$0.23 | −$0.47 | $4.78 | $4.35 | −1,985.7% | 2 up · 0 down |
| Next fiscal year (2027) | $5.24 | $5.24 | $4.35 | $5.54 | $5.07 | −3.2% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ANAB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ANAB beat in 9 of 12.
What analysts expect from ANAB
8 analysts cover AnaptysBio; their consensus rating is strong buy (4.62 on a 1–5 scale, where 5 is a strong buy). The average price target is $87.25, 87.2% above the latest close of $46.61. Analysts expect earnings of $4.35 per share for 2026, +1,045.7% from a year earlier. For 2027 the average estimate is $5.07 per share on revenue of $171.3 million. AnaptysBio beat the EPS estimate in 9 of the last 12 quarters.
Related: ANAB income statement, ANAB key metrics, ANAB chart. See the ANAB stock overview for the latest quote and news.
ANAB forecast FAQ
What is AnaptysBio's price target?
The average analyst price target for AnaptysBio is $87.25, 87.2% above the latest close of $46.61.
Is AnaptysBio a buy, hold or sell?
Of 8 analysts covering AnaptysBio, 5 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is AnaptysBio's EPS forecast?
Analysts forecast $4.35 per share for 2026 (range $2.49 to $7.06); for 2027 the estimate is $5.07.
What is AnaptysBio's revenue forecast?
The average revenue estimate for 2026 is $101.1 million, growth of −56.9%; for 2027 it is $171.3 million.
When does AnaptysBio report earnings?
AnaptysBio is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes; the EPS estimate is $0.41.
Does AnaptysBio usually beat earnings estimates?
AnaptysBio reported EPS at or above the analyst estimate in 9 of the last 12 quarters.